Valuation: Ind-Swift Laboratories Limited

Market Cap 3.12TCr 33Cr 29Cr 27Cr 25Cr 47Cr 47Cr 325.99Cr 127.81Cr 1.63TCr 123.54Cr 120.91Cr 5.2TCr P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 2.7TCr 28Cr 25Cr 23Cr 21Cr 40Cr 41Cr 282.04Cr 110.58Cr 1.41TCr 106.88Cr 104.61Cr 4.5TCr EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
33.96%
Yield 2025 *
-
Yield 2026 -
1 day-0.35%
1 week-0.84%
Current month-7.91%
1 month-5.64%
3 months+53.00%
6 months+157.74%
Current year+306.13%
1 week 345
Extreme 345
377.2
1 month 345
Extreme 345
424.75
Current year 87.25
Extreme 87.25
424.75
1 year 87.15
Extreme 87.15
424.75
3 years 68.72
Extreme 68.72
424.75
5 years 52.65
Extreme 52.65
424.75
10 years 15
Extreme 15
424.75
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/09/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-0.84%+241.54%+293.84% 33Cr
+0.43%+6.59%+56.57%+107.01% 1,12000Cr
+0.90%-2.25%+32.26%+67.33% 62TCr
+0.71%+3.24%+24.33%+91.20% 50TCr
-0.13%+5.98%+33.66%+52.01% 37TCr
+0.52%+0.24%+72.13%+43.10% 36TCr
-0.95%+4.70%+19.65%+43.09% 29TCr
-1.98%+3.73%-0.89%+17.28% 26TCr
-0.35%+4.25%+44.74%+52.51% 23TCr
-0.75%+3.32%+27.18%+96.05% 19TCr
Average -0.19%+2.93%+55.12%+86.34% 39.41TCr
Weighted average by Cap. +0.13%+3.52%+39.35%+73.53%

Financials

2025 2026
Net sales 561.71Cr 5.92Cr 5.26Cr 4.88Cr 4.44Cr 8.37Cr 8.51Cr 59Cr 23Cr 293.12Cr 22Cr 22Cr 934.44Cr 649.14Cr 6.84Cr 6.08Cr 5.64Cr 5.13Cr 9.67Cr 9.83Cr 68Cr 27Cr 338.75Cr 26Cr 25Cr 1.08TCr
Net income 250.48Cr 2.64Cr 2.35Cr 2.17Cr 1.98Cr 3.73Cr 3.79Cr 26Cr 10Cr 130.71Cr 9.9Cr 9.69Cr 416.68Cr 43Cr 45.44L 40.39L 37.44L 34.06L 64.27L 65.3L 4.5Cr 1.76Cr 23Cr 1.71Cr 1.67Cr 72Cr
Net Debt -426.55Cr -4.49Cr -4Cr -3.7Cr -3.37Cr -6.36Cr -6.46Cr -45Cr -17Cr -222.59Cr -17Cr -17Cr -709.58Cr -421.25Cr -4.44Cr -3.95Cr -3.66Cr -3.33Cr -6.28Cr -6.38Cr -44Cr -17Cr -219.82Cr -17Cr -16Cr -700.77Cr
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
19/26/19 ₹359.65 +0.11% 75,150
16/26/16 ₹359.25 +0.36% 3,09,979
15/26/15 ₹357.95 -3.18% 2,62,152
14/26/14 ₹369.70 +2.31% 3,54,561
13/26/13 ₹361.35 +0.08% 3,65,436
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock